Jamming bacterial communication: New approaches for the treatment of infectious diseases

Jacqueline Njoroge, Vanessa Sperandio

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

The global rise of anti-microbial resistance, combined with the rapid rate of microbial evolution, and the slower development of novel antibiotics, underscores the urgent need for innovative therapeutics. We are facing a post-antibiotic era with a decreased armamentarium to combat infectious diseases. Development of novel drugs will rely on basic research aimed to increase our understanding of bacterial pathogenesis and the inter-cellular chemical signalling among bacterial cells. Such basic science, when combined with contemporary drug discovery technologies, may be translated into therapeutic applications to combat bacterial infections. In this review, we discuss many strategies aimed to interfere with bacterial cell-to-cell signalling via the quorum-sensing (QS) pathway to inhibit bacterial virulence and/or the development of microbial communities (known as biofilms), which are refractory to antibiotic treatment. QS antagonists should be viewed as blockers of pathogen- icity rather than as anti-microbials and because QS is not involved in bacterial growth, inhibition of QS should not yield a strong selective pressure for development of resistance. QS inhibitors (QSIs) hold great expectations and we look forward to their application in fighting bacterial infections.

Original languageEnglish (US)
Pages (from-to)201-210
Number of pages10
JournalEMBO Molecular Medicine
Volume1
Issue number4
DOIs
StatePublished - Jul 2009

Fingerprint

Quorum Sensing
Communicable Diseases
Anti-Bacterial Agents
Bacterial Infections
Virulence
Drug Discovery
Biofilms
Technology
Therapeutics
Growth
Research
Pharmaceutical Preparations

Keywords

  • Enterohemorrhagic E. coli (EHEC)
  • Inter-kingdom signalling
  • Pseudomonas aeruginosa
  • Quorum sensing
  • Staphylococcus aureus

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Jamming bacterial communication : New approaches for the treatment of infectious diseases. / Njoroge, Jacqueline; Sperandio, Vanessa.

In: EMBO Molecular Medicine, Vol. 1, No. 4, 07.2009, p. 201-210.

Research output: Contribution to journalArticle

@article{025e8ce43a314b328b09fd150b0fc401,
title = "Jamming bacterial communication: New approaches for the treatment of infectious diseases",
abstract = "The global rise of anti-microbial resistance, combined with the rapid rate of microbial evolution, and the slower development of novel antibiotics, underscores the urgent need for innovative therapeutics. We are facing a post-antibiotic era with a decreased armamentarium to combat infectious diseases. Development of novel drugs will rely on basic research aimed to increase our understanding of bacterial pathogenesis and the inter-cellular chemical signalling among bacterial cells. Such basic science, when combined with contemporary drug discovery technologies, may be translated into therapeutic applications to combat bacterial infections. In this review, we discuss many strategies aimed to interfere with bacterial cell-to-cell signalling via the quorum-sensing (QS) pathway to inhibit bacterial virulence and/or the development of microbial communities (known as biofilms), which are refractory to antibiotic treatment. QS antagonists should be viewed as blockers of pathogen- icity rather than as anti-microbials and because QS is not involved in bacterial growth, inhibition of QS should not yield a strong selective pressure for development of resistance. QS inhibitors (QSIs) hold great expectations and we look forward to their application in fighting bacterial infections.",
keywords = "Enterohemorrhagic E. coli (EHEC), Inter-kingdom signalling, Pseudomonas aeruginosa, Quorum sensing, Staphylococcus aureus",
author = "Jacqueline Njoroge and Vanessa Sperandio",
year = "2009",
month = "7",
doi = "10.1002/emmm.200900032",
language = "English (US)",
volume = "1",
pages = "201--210",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Jamming bacterial communication

T2 - New approaches for the treatment of infectious diseases

AU - Njoroge, Jacqueline

AU - Sperandio, Vanessa

PY - 2009/7

Y1 - 2009/7

N2 - The global rise of anti-microbial resistance, combined with the rapid rate of microbial evolution, and the slower development of novel antibiotics, underscores the urgent need for innovative therapeutics. We are facing a post-antibiotic era with a decreased armamentarium to combat infectious diseases. Development of novel drugs will rely on basic research aimed to increase our understanding of bacterial pathogenesis and the inter-cellular chemical signalling among bacterial cells. Such basic science, when combined with contemporary drug discovery technologies, may be translated into therapeutic applications to combat bacterial infections. In this review, we discuss many strategies aimed to interfere with bacterial cell-to-cell signalling via the quorum-sensing (QS) pathway to inhibit bacterial virulence and/or the development of microbial communities (known as biofilms), which are refractory to antibiotic treatment. QS antagonists should be viewed as blockers of pathogen- icity rather than as anti-microbials and because QS is not involved in bacterial growth, inhibition of QS should not yield a strong selective pressure for development of resistance. QS inhibitors (QSIs) hold great expectations and we look forward to their application in fighting bacterial infections.

AB - The global rise of anti-microbial resistance, combined with the rapid rate of microbial evolution, and the slower development of novel antibiotics, underscores the urgent need for innovative therapeutics. We are facing a post-antibiotic era with a decreased armamentarium to combat infectious diseases. Development of novel drugs will rely on basic research aimed to increase our understanding of bacterial pathogenesis and the inter-cellular chemical signalling among bacterial cells. Such basic science, when combined with contemporary drug discovery technologies, may be translated into therapeutic applications to combat bacterial infections. In this review, we discuss many strategies aimed to interfere with bacterial cell-to-cell signalling via the quorum-sensing (QS) pathway to inhibit bacterial virulence and/or the development of microbial communities (known as biofilms), which are refractory to antibiotic treatment. QS antagonists should be viewed as blockers of pathogen- icity rather than as anti-microbials and because QS is not involved in bacterial growth, inhibition of QS should not yield a strong selective pressure for development of resistance. QS inhibitors (QSIs) hold great expectations and we look forward to their application in fighting bacterial infections.

KW - Enterohemorrhagic E. coli (EHEC)

KW - Inter-kingdom signalling

KW - Pseudomonas aeruginosa

KW - Quorum sensing

KW - Staphylococcus aureus

UR - http://www.scopus.com/inward/record.url?scp=77949918387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949918387&partnerID=8YFLogxK

U2 - 10.1002/emmm.200900032

DO - 10.1002/emmm.200900032

M3 - Article

C2 - 20049722

AN - SCOPUS:77949918387

VL - 1

SP - 201

EP - 210

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 4

ER -